Wednesday, April 18, 2018
News Roundup

Was it right this boy got a chance to live?

Just hours after social media supporters of a dying 7-year-old boy pressured a reluctant biotech company into giving him an experimental medication, the backlash began. Is "it right to save 1 child and not the rest?" wondered one commenter on a news forum. "It's really not fair to the thousands of others that were turned down just because they didn't make a big public outcry," said another.

The Herald-Sun newspaper in Durham, N.C., where the company that makes the drug is based, said it was glad for the boy's sake that he was able to get the medicine. "But the process leaves us pained," the editorial board wrote. "This is no way to make health-care decisions."

The story of how Joshua Hardy — a first-grader from Fredericksburg, Va., who is fighting off an infection after getting a bone-marrow transplant — got access to an unapproved treatment when others with similar requests were turned down highlights the ethical conundrums facing doctors, companies and regulators in the era of Facebook and Twitter.

In the days leading up to the drug company's change of heart March 11, contrasting photos of Josh — smiling at baseball games and then lying in his hospital bed with tubes sticking out of his body — were all over the Internet. He has beaten cancer four times since he was 9 months old. But the disease has left his body without much of an immune system, and in February he was infected with a virus that left him close to death.

Nearly 20,000 people signed a petition supporting "compassionate use" for Josh, which allows a drug to be administered outside of a clinical trial. Hundreds bombarded Chimerix, a small, publicly traded company that makes the drug, with emails and calls on the boy's behalf.

Critics of the strategy say they sympathize with Josh's parents and admire them for being willing to do anything to save their child, but they decry the crowdsourcing of medical decisions and warn that the case may set a dangerous precedent.

"You couldn't get a more troubling and impossible-to-resolve moral dilemma than this one," said Arthur Caplan, director of the division of medical ethics at New York University's Langone Medical Center.

From the perspective of the public and future patients, it's best for the company to focus on getting the drug approved as soon as possible so that the largest number of people can be helped, Caplan said. But from a patient's point of view, getting immediate access to the drug is what's important. "It's a trade-off between the public good versus self-interest," Caplan said. "They conflict. There is no way of getting around it."

Richard Plotkin, a 69-year-old retired trial lawyer from New Jersey who started the Max Cure Foundation after his grandson was diagnosed with lymphoma at age 4 and was at the center of efforts to save Josh, defends the campaign as necessary. "I knew we had at the latest until the end of the week before the boy would die, and the best way to make a company change its mind — fast — is to get the public involved," Plotkin said.

The parents of 11-year-old Sarah Murnaghan also have faced intense criticism. The Philadelphia girl received two lung transplants (the first one failed) last June after her parents launched a Change.org petition that got 370,000 signatories and sued in an effort to get their daughter an organ more quickly.

Janet Murnaghan said she knows that not everyone agrees with the way her daughter's case was resolved — a judge ordered the transplant network to put her on the adult list, and she jumped to the top because of the severity of her condition — but she believes it did the public good by demanding that patients have a larger voice in how organs are allocated.

Since the early days of the AIDS epidemic, patients with life-threatening conditions have become increasingly vocal about demanding access to drugs still in development. The Food and Drug Administration later created rules for expanded access or compassionate use to allow what it says is "broad and equitable access" to those treatments. But the program remains limited. Since 2009, the agency has approved an average of 1,030 applications each year.

• • •

Most patients' requests never make it to that stage.

Before the FDA gets involved, companies must agree to allow their drug to be used. But many companies are reluctant to do so for a host of reasons — legal, financial and logistical — and, in most cases, they hold firm despite intense public pressure.

Andrea Sloan, 45, a lawyer whose case drew the support of several Texas legislators as well as Newt Gingrich, died Jan. 1 while fighting for a drug to treat ovarian cancer made by BioMarin Pharmaceutical. Nick Auden, a Denver father of three with melanoma who was able to gather 500,000 signatures for a petition for compassionate use of a Merck drug, died last November without getting the treatment. He was 41.

The companies argue that if something goes wrong with a patient who gets a drug outside the clinical-trial process, it could slow down their larger development program while the FDA investigates. Moreover, insurance companies typically won't pay for unapproved treatments, so either the drug companies have to bear the costs or give the treatment only to those who can afford it.

Even if those challenges can be overcome, companies say, there are ethical issues.

Kenneth Moch, chief executive of Chimerix, which makes the drug that the Hardys were seeking, said that until 2012 the company had a large compassionate-use program but had to discontinue it to focus its limited resources — it has only 60 employees and is not profitable — on getting the drug approved. During the past two years, Chimerix has nonetheless received 200 applications for compassionate use. All of the requests were turned down. "Every one of those is heart-wrenching,'' Moch said. "But making it available for one child, whatever the reason, as an exception is not equitable distribution."

Chimerix turned down the Hardys' requests, too. But after several days of intense phone calls with officials at the FDA's Division of Anti-Viral Products — who heard about Josh's plight through the media — they worked out a solution.

Instead of getting the drug through the compassionate-use program, Josh got it through the clinical-trial process. Although he wasn't eligible for the trial in progress — it is for adults with a different condition — the FDA offered to immediately green-light a new clinical trial that would be designed for pediatric patients with Josh's condition.

In this way, medical experts say, the FDA created a wall that would allow Chimerix to give Josh and up to 19 other children the drug for free without opening the floodgates to others.

The deal was also a big win for Chimerix: No only did it solve its public relations crisis, it allowed the company to cut through the red tape that is typically required to get a clinical trial approved. And the company's stock has jumped.

• • •

Josh received his second dose of the treatment — an antiviral drug called brincidofovir — last Wednesday. He remains in intensive care at St. Jude Children's Research Hospital in Memphis.

His mother, Aimee Hardy, wrote hopefully on Facebook that the virus in Josh's blood is replicating more slowly, and he is in less pain than before. "Glory to God," she said, "the medicine is working."

• Got a comment on this story? Email [email protected] Please include your full name and city if you want your comments considered for publication.

Comments
Lightning stands up to Devils, pushes its way to 3-1 series lead

Lightning stands up to Devils, pushes its way to 3-1 series lead

NEWARK, N.J. — Bachman-Turner Overdrive's Taking Care of Business shook the walls of the Lightning locker room not long after it dispatched the Devils in Wednesday's Game 4 of their first-round playoff series.The 3-1 win was sparked by Nikita K...
Updated: 2 hours ago

High school scoreboard for April 18

Wednesday’s scoreboardSoftballAdmiral Farragut 2, Boca Ciega 1Springstead 10, Nature Coast 4
Updated: 2 hours ago
Lightning-Devils: How Tampa Bay worked its way to a 3-1 series lead

Lightning-Devils: How Tampa Bay worked its way to a 3-1 series lead

Times columnist Tom Jones gives his thoughts while watching the broadcast of Game 4 of the series between the Lightning and Devils:Hard work beats everythingWe watch the Lightning all season long and marvel at its skill. Nikita Kucherov, Steven ...
Updated: 2 hours ago
Political skirmish erupts over plan to revamp Hillsborough commission

Political skirmish erupts over plan to revamp Hillsborough commission

TAMPA — A political fight over the makeup of Hillsborough County government could be heading to voters to decide.After a discussion divided along party lines, commissioners voted 5-2 Wednesday to move ahead with a plan to overhaul the structure of th...
Updated: 4 hours ago
Largo police release video as State Attorney clears officer in shooting

Largo police release video as State Attorney clears officer in shooting

LARGO — The Pasco-Pinellas state attorney cleared a Largo police officer who fatally shot a 30-year-old man last month.The letter from State Attorney Bernie McCabe said Officer Matthew Steiner was "in imminent fear for his life" during the March 23 e...
Updated: 4 hours ago
2 men spread affirmations in New Hampshire; bipartisan bill calls for VA to study pot; 3 men convicted in plot to bomb Somali refugees; more in U.S. news

2 men spread affirmations in New Hampshire; bipartisan bill calls for VA to study pot; 3 men convicted in plot to bomb Somali refugees; more in U.S. news

New HampshireWe need more of these signsTwo men are trying to spread some positivity with their feel-good signs. NH1 reported Greg Amaral and Wendell Walker have stood in downtown Nashua with signs carrying positive messages each weekend since Easter...
Updated: 4 hours ago

Lottery resultsNumbers drawn after 9 p.m. aren’t available by our deadlines. For results, please go to tampabay.com/lottery.Pick 2, 3, 4, 5Wed., April 18, midday:15 112 6177e_SRit28928Wed., April 18, evening:11 318 7120e_SRit93676LottoWed., April 18:...
Updated: 4 hours ago
Diamond shines light on ‘lost planet,’ says study; Merkel condemns attack on 2 men in Jewish skullcaps in Berlin; more in world news

Diamond shines light on ‘lost planet,’ says study; Merkel condemns attack on 2 men in Jewish skullcaps in Berlin; more in world news

WorldDiamond sheds light on ‘lost planet’Fragments of a meteorite that fell to Earth about a decade ago provide compelling evidence of a lost planet that once roamed our solar system, according to a study published Tuesday. Researchers from Switzerla...
Updated: 6 hours ago

Hillsborough targets bilingual teachers’ aides in latest school cuts

TAMPA — The Hillsborough County School District, with a large and growing population of children from foreign cultures, is reducing the ranks of teacher aides who help them master the English language.Next year’s workforce will have about 164 fewer p...
Updated: 6 hours ago
Anonymous Rays rally to beat Rangers 4-2, win series

Anonymous Rays rally to beat Rangers 4-2, win series

ST. PETERSBURG — Even before they lost several of the hitters they were relying most on to injuries, the Rays did not exactly have a lineup built on intimidation.Their own owner said opening day that he expected them to rank among the least pro...
Updated: 6 hours ago